A Randomised, Double-blind, Three-arm, Parallel Group, Single Dose, Phase 1 Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent, and EU-Dupixent in Healthy Adult Participants
Latest Information Update: 02 Feb 2026
At a glance
- Drugs CKD 706 (Primary) ; Dupilumab
- Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Eosinophilic oesophagitis; Nasal polyps; Prurigo nodularis; Rhinosinusitis
- Focus First in man; Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 30 Jan 2026 New trial record